Pharmaceutical Contract Development and Manufacturing Organization (CDMO) / Specialty Chemicals
Strategic Profile
Lifecore offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products and brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical companies across multiple therapeutic categories. The company was recently added to the Nasdaq Biotech Index, reflecting its growing market presence.
Cyborg Score Rationale
Lifecore operates in a niche but attractive CDMO space with decades of expertise in hyaluronic acid manufacturing and injectables. Recent inclusion in the Nasdaq Biotech Index validates market position. However, stock trading near $8 indicates modest valuation, and the company faces capacity utilization challenges as noted in recent communications.
Top Insights
Recently added to Nasdaq Biotech Index (December 2025), signaling market validation and increased institutional investor access
Operates three cGMP facilities with FDA approvals and international certifications across Europe, Japan, and Brazil
Pioneer in proprietary fermentation-based hyaluronic acid process with 40+ years of manufacturing expertise
CDMO business model positioned to benefit from biopharmaceutical outsourcing trends and injectable pharmaceutical growth
Named Competitors
Injectables Contract Manufacturing — Global CDMO with broad injectable and biologics capabilities
Injectable CDMO Services — Integrated CDMO with sterile manufacturing focus
Fill-Finish and Formulation — Large-scale CDMO for injectables and pharmaceuticals
Recent Developments
(February 2026) Participation announced at DCAT Week 2026
(December 2025) Added to Nasdaq Biotech Index effective December 22, 2025
(January 2026) Inducement grants announced under Nasdaq listing rules
Open the full interactive Lifecore Biomedical, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.